Back to Browse Journals » Cancer Management and Research » Volume 4

Pelvic exenteration for colorectal cancer: oncologic outcome in 59 patients at a single institution

Authors López-Basave HN, Morales-Vásquez F, Herrera-Gómez Á, Padilla Rosciano A, Meneses-Garcíá A, Ruiz-Molina JM

Published Date October 2012 Volume 2012:4 Pages 351—356

DOI http://dx.doi.org/10.2147/CMAR.S34545

Received 1 June 2012, Accepted 14 August 2012, Published 11 October 2012

Horacio N López-Basave, Flavia Morales-Vásquez, Ángel Herrera-Gómez, Alejandro Padilla Rosciano, Abelardo Meneses-García, Juan M Ruiz-Molina

Department of Gastroenterology, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico

Background: Pelvic exenteration (PE) continues to be the only curative option in selected patients with advanced or recurrent pelvic neoplasms. A current debate exists concerning the appropriate selection of patients for PE, with the most important factor being the absence of extrapelvic disease.
Aim: To evaluate the outcome of patients submitted to exenterative surgery.
Patients and methods: A review of the clinical charts of patients with colorectal cancer who underwent PE between January 1994 and June 2010 at the Institute National of Cancerología in Mexico City was performed.
Results: We selected 59 patients, 53 of whom were females (90%), and six of whom were males (10%). Mean age at the time of diagnosis was 50 years (range, 21-77 years). A total of 51 patients underwent posterior PE (86%), and eight patients underwent total PE (14%). Operative mortality occurred in two cases (3%), and 29 patients developed complications (49%). Overall, 11 patients (19%) experienced local failure with mean disease-free survival time of 10.2 months. After a mean follow-up of 28.3 months, nine patients are still alive without evidence of the disease (15%).
Conclusions: PE should be considered in advanced colorectal cancer without extrapelvic metastatic disease. PE is accompanied by considerable morbidity (49%) and mortality (3%), but local control is desirable. Overall survival justifies the use of this procedure in patients with primary or recurrent locally advanced rectal cancer.

Keywords: pelvic exenteration, colorectal cancer

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Gastric cancer in young people under 30 years of age: worse prognosis, or delay in diagnosis?

Lopez-Basave HN, Morales-Vasquez F, Ruiz-Molina JM, Namendys-Silva SA, Vela-Sarmiento I, Ruan JM, Padilla Rosciano AE, Calderillo-Ruiz G, Diaz-Romero C, Herrera-Gomez A, Meneses-Garcia AA

Cancer Management and Research 2013, 5:31-36

Published Date: 4 April 2013

Readers of this article also read:

Gastric cancer in young people under 30 years of age: worse prognosis, or delay in diagnosis?

Lopez-Basave HN, Morales-Vasquez F, Ruiz-Molina JM, Namendys-Silva SA, Vela-Sarmiento I, Ruan JM, Padilla Rosciano AE, Calderillo-Ruiz G, Diaz-Romero C, Herrera-Gomez A, Meneses-Garcia AA

Cancer Management and Research 2013, 5:31-36

Published Date: 4 April 2013

Long-term tolerability of topical diclofenac sodium 1% gel for osteoarthritis in seniors and patients with comorbidities

Peniston JH, Gold MS, Wieman MS, Alwine LK

Clinical Interventions in Aging 2012, 7:517-523

Published Date: 20 November 2012

Nodal involvement pattern in resectable lung cancer according to tumor location

Saeteng S, Tantraworasin A, Euathrongchit J, Lertprasertsuke N, Wannasopha Y

Cancer Management and Research 2012, 4:151-158

Published Date: 7 June 2012

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

Imaging of peripheral vascular disease

Mo Al-Qaisi, David M Nott, David H King, Sam Kaddoura, Mo Hamady

Reports in Medical Imaging 2009, 2:25-34

Published Date: 27 March 2009

Selective p38α mitogen-activated protein kinase inhibitor attenuates lung inflammation and fibrosis in IL-13 transgenic mouse model of asthma

Jing Ying Ma, Satyanarayana Medicherla, Irene Kerr, Ruban Mangadu, Andrew A Protter, Linda S Higgins

Journal of Asthma and Allergy 2008, 1:31-44

Published Date: 16 November 2008

Manipulation of pain catastrophizing: An experimental study of healthy participants

Joel E Bialosky, Adam T Hirsh, Michael E Robinson, Steven Z George

Journal of Pain Research 2008, 1:35-41

Published Date: 11 November 2008